All results

1 results for impact

• DOTS (20-0002)

  This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of…

  Ages

  18 Years - 99 Years

  Sexes

  All